Literature DB >> 23817324

IBD: Antibodies to anti-TNF therapy--consequences for IBD management.

Welmoed K van Deen1, Daniel W Hommes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23817324     DOI： 10.1038/nrgastro.2013.118

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  8 in total

1.  The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.

Authors:  S Ben-Horin; Y Mazor; H Yanai; Y Ron; U Kopylov; M Yavzori; O Picard; E Fudim; Y Maor; A Lahat; D Coscas; R Eliakim; I Dotan; Y Chowers
Journal:  Aliment Pharmacol Ther       Date:  2012-01-30       Impact factor: 8.171

2.  The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.

Authors:  Shomron Ben-Horin; Miri Yavzori; Lior Katz; Uri Kopylov; Orit Picard; Ella Fudim; Daniel Coscas; Simon Bar-Meir; Itamar Goldstein; Yehuda Chowers
Journal:  Gut       Date:  2010-06-02       Impact factor: 23.059

3.  Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.

Authors:  C Steenholdt; Y Palarasah; K Bendtzen; A Teisner; J Brynskov; B Teisner; C H Nielsen
Journal:  Aliment Pharmacol Ther       Date:  2013-05-07       Impact factor: 8.171

Review 4.  Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.

Authors:  Kavinderjit S Nanda; Adam S Cheifetz; Alan C Moss
Journal:  Am J Gastroenterol       Date:  2012-11-13       Impact factor: 10.864

5.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

Authors:  Edouard Louis; Jean-Yves Mary; Gwenola Vernier-Massouille; Jean-Charles Grimaud; Yoram Bouhnik; David Laharie; Jean-Louis Dupas; Hélène Pillant; Laurence Picon; Michel Veyrac; Mathurin Flamant; Guillaume Savoye; Raymond Jian; Martine Devos; Raphaël Porcher; Gilles Paintaud; Eric Piver; Jean-Frédéric Colombel; Marc Lemann
Journal:  Gastroenterology       Date:  2011-09-22       Impact factor: 22.682

6.  Antibody response to infliximab and its impact on pharmacokinetics can be transient.

Authors:  Niels Vande Casteele; Ann Gils; Sharat Singh; Linda Ohrmund; Scott Hauenstein; Paul Rutgeerts; Séverine Vermeire
Journal:  Am J Gastroenterol       Date:  2013-02-19       Impact factor: 10.864

Review 7.  The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.

Authors:  Sandra Garcês; Jocelyne Demengeot; Elizabeth Benito-Garcia
Journal:  Ann Rheum Dis       Date:  2012-12-06       Impact factor: 19.103

Review 8.  Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.

Authors:  Pauline A van Schouwenburg; Theo Rispens; Gerrit Jan Wolbink
Journal:  Nat Rev Rheumatol       Date:  2013-02-12       Impact factor: 20.543
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.